The CyberKnife System’s non-invasive treatment for cancer provides radiotherapy treatment in 1 to 5 sessions and has helped hundreds of thousands of patients worldwide.
CyberKnife a form of stereotactic radiosurgery, shows high success rates, particularly for certain cancers.
For example, prostate cancer treatment with CyberKnife can achieve 97-100% disease-free survival at five years for low-risk patients.
Similarly, it demonstrates high local control rates for kidney and lung tumors, with studies showing significant tumor control and symptom reduction.
However, success rates can vary based on factors like cancer type, stage, and patient characteristics.
Success Rates by Cancer Type:
Prostate Cancer: CyberKnife treatment for prostate cancer shows excellent long-term cancer control, with disease-free survival rates of 97-100% for low-risk patients at five years, and 93% at 10 years. For intermediate-risk patients, the rates are 88-97% at five years.
Lung Cancer: Studies on elderly patients with presumed stage I lung cancer show 1, 3, and 5-year cancer-specific survival rates of 100%, 81.3%, and 67% respectively. A separate study found a 92% success rate in treating small lung tumors with CyberKnife.
Liver Cancer: One study showed a one-year overall survival rate of 78.5% and a two-year survival rate of 50.4% for liver cancer patients. Another study found that 89.8% of patients showed no progression of cancer beyond the liver at two years.
Kidney Cancer: CyberKnife, as a first-line treatment for kidney cancer, can achieve local control in 90% of patients.
Brain Metastases: Studies on brain metastases show that CyberKnife can stabilize or significantly improve the performance status of around 90% of patients.
Spinal Lesions: CyberKnife can achieve a local control rate of nearly 90% in patients with spinal lesions, with radicular pain relief in 25-85% of patients.
Meningiomas: CyberKnife stereotactic radiosurgery has a high success rate for treating brain and spine meningiomas, with about 95% of tumors stopping growth after treatment.
Factors Affecting Success Rates:
Cancer Type and Stage: Success rates vary depending on the type of cancer and its stage.
Patient Characteristics: Factors like age, overall health, and tumor location can influence outcomes.
Tumor Size and Location: CyberKnife is particularly effective for localized tumors, including those in the brain, spine, lung, liver, pancreas, prostate, and kidneys.
Advantages of CyberKnife:
Precision: CyberKnife delivers highly focused radiation to the tumor, minimizing damage to surrounding healthy tissue.
Non-Invasive: It’s a non-invasive procedure, unlike surgery, with no incisions or hospital stay required.
Fewer Treatment Sessions: CyberKnife often allows for fewer treatment sessions compared to traditional radiation therapy.
Reduced Side Effects: It can result in fewer side effects compared to other treatment options.
If you have questions or want to set up a consultation, call one of the most experienced CyberKnife teams worldwide at the CyberKnife Center of Miami at 305-279-2900.